LETTER RE: Postmarketing adverse drug reactions: A duty to report?
KhicharShubhakaran, Dr. S. N. Medical College, Jodhpur, India, drkhicharsk@gmail.com
; Rekha Jakur Khichar; Dr. S. N. Medical College, Jodhpur, India
Submitted June 21, 2014
We read with interest the article by Klein and Bourdette,1 which highlights the ethical issues pertaining
to adverse drug reactions. We agree that adverse reactions
should be communicated to the manufacturer of the drug in
question. However, sometimes the manufacturer will defer
blame to an aspect of drug dispensing or concurrent drug
use, so this is only the first avenue of recourse. It is
also important to report adverse effects in a reputable and
widely distributed medical journal. Unfortunately, case
reports are being given less and less import in many of
these journals. Case reports are seen as not novel, simply
confirmative, and less interesting to readers. Let us not
forget that our knowledge of neurology is fashioned case by
case.
Disclosures: The authors report no disclosures
Reference
1. Klein E, Bourdette D. Postmarketing adverse drug
reactions: a duty to report? Neurol Clin Pract 2013;3:288-294.
Disclosures: The authors report no disclosures
Reference
1. Klein E, Bourdette D. Postmarketing adverse drug reactions: a duty to report? Neurol Clin Pract 2013;3:288-294.